Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.

A, Östör; den Bosch F, Van; K, Papp; C, Asnal; R, Blanco; J, Aelion; G, Alperovich; W, Lu; Z, Wang; AM, Soliman; A, Eldred; L, Barcomb; A, Kivitz

doi:10.1136/annrheumdis-2021-221048

Public

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.

Shared by NobleBlocks on Nov 23, 2021 • 12:00 AM UTC

Authors:

Östör A

Van den Bosch F

Papp K

Abstract

<h4>Objectives</h4>Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA who had previous inadequate response o...

Subject

Arthritis

Biological Therapy

Psoriatic

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!